ArchiveJune 2017

What’s Torsades?

If you read the post below you may, like I, ask what is Torsades de pointes,  We know that fingolimod can cause heart arrhythmias on first dose. Torsades de pointes is another heart problem Torsades de pointes or torsade depointes (TdP or simply torsade(s)) translated as “twisting of the points”), is a specific type of abnormal heart...

#GuestPost & #NeuroSpeak: fingolimod and azole antifungals

If you are on fingolimod be careful about taking antifungal drugs; they may interact with each other #GuestPost #NeuroSpeak I don’t normally post unsolicited guest-posts on this blog. However, the author of the following Facebook post convinced me that what she had to say was important enough for me to reconsider this position and repost verbatim what she sent me. The latter information is...

Liver problem after generic glatiramer acetate: Cop Wars

Sabatino JJ Jr, Mehta NJ, Kakar S, Zamvil SS, Cree BAC. Acute liver injury in a Glatopa-treated patient with MS. Neurol Neuroimmunol Neuroinflamm. 2017 Jun 5;4(4):e368. Recently ProfG reported on a case of liver problems after daclizumab. This has happened after treatment with CRAB drugs and this is a case report of a new generic copaxone. It was reported that there the problem...

#ThinkHand: can we afford to ignore the importance of hand function to pwMS?

Our #ThinkHand campaign may yet prove useful in making the case for using ocrelizumab to treat PPMS You may remember our ECTRIMS 2016 #ThinkHand campaign and our handmade cardboard poster, helium balloons and T-shirts. DrM&M in front of our poster; please note the helium balloons!  What is important is the results of the survey that clearly shows how important hand function is for people...

#ThinkHand: people with PPMS need your help?

We need your help to raise awareness about hand function in MS #ThinkHand In the last few days I have become increasingly anxious about the regulators, payers and healthcare professional letting down pwPPMS. Despite having the first positive trial of a DMT in PPMS there are many hurdles to overcome to get ocrelizumab to the people who need it, i.e. people with active PPMS. It seems as if the...

My drug is better than low hanging fruit. Rituximab better than CRAB

Spelman T, Frisell T, Piehl F, Hillert J.Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2017 Jun 1:1352458517713668. OBJECTIVE:To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer acetate (GA) or...

#ClinicSpeak & #PoliticalSpeak: why should people with primary progressive MS be treated as 2nd-class citizens?

Will pwPPMS be forced to pay for ocrelizumab privately? #ClinicSpeak #PoliticalSpeak My blog post yesterday regarding equitable access to healthcare and HSCT generated some lively discussion. One reader asked: ‘Any idea when ocrelizumab will be available in Europe for PPMS? It isn’t fair that the FDA has approved the drug and we are still waiting and losing brain’...

Blocking NOGO to make nerves

Ineichen BV, Kapitza S, Bleul C, Good N, Plattner PS, Seyedsadr MS, Kaiser J, Schneider MP, Zörner B, Martin R, Linnebank M, Schwab ME.Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology.Acta Neuropathol. 2017 doi: 10.1007/s00401-017-1745-3 Two hallmarks of chronic multiple sclerosis lesions are the absence of significant spontaneous...

#NewsSpeak: do you want to make a difference?

Do you want to make a difference to world of MS? #NewsSpeak #OffLabel One of our long running campaigns has been trying to promote access to treatments for pwMS in resource poor environments. For the last 2 years we have been promoting an Essential #OffLabel list of DMTs for resource poor settings. The MS International Federation (MSIF), who represents MS Societies from all over the world...

Staggeringly profitable business of Science publishing

If you are interested in the publishing process you may want to read this. We have been telling you about the publication process and this article adds to the madness.  Is the staggeringly profitable business of scientific publishing bad for science? by Stephen Buranyi CLICK Here In addition to this, the Open access system has turned it all into a bottomless sink. Will it change…...

Translate

Categories

Recent Posts

Recent Comments

Archives